Search
Sipatrigine
go.drugbank.com/drugs/DB21032ExperimentalThe usage of the INN stem '-trigine' in the name indicates that Sipatrigine is a sodium channel blocker, signal transduction modulator. Sipatrigine has a monoisotopic molecular weight of 371.05 Da.
Nemazoline
go.drugbank.com/drugs/DB21115ExperimentalThe usage of the INN stem '-azoline' in the name indicates that Nemazoline is a antihistaminic or local vasoconstrictor, antazoline derivative.
Ebrotidine
go.drugbank.com/drugs/DB21220ExperimentalThe usage of the INN stem '-tidine' in the name indicates that Ebrotidine is a histamine- H2-receptor antagonist, cimetidine derivative. Ebrotidine has a monoisotopic molecular weight of 475.98 Da.
Aloracetam
go.drugbank.com/drugs/DB21233ExperimentalThe usage of the INN stem '-racetam' in the name indicates that Aloracetam is a piracetam type amide type nootrope agent. Aloracetam has a monoisotopic molecular weight of 208.12 Da.
Adarigiline
go.drugbank.com/drugs/DB21418ExperimentalThe usage of the INN stem '-giline' in the name indicates that Adarigiline is a monoamine oxydase (MAO)-inhibitor type B. Adarigiline has a monoisotopic molecular weight of 360.08 Da.
Oxmetidine
go.drugbank.com/drugs/DB21430ExperimentalThe usage of the INN stem '-tidine' in the name indicates that Oxmetidine is a histamine- H2-receptor antagonist, cimetidine derivative. Oxmetidine has a monoisotopic molecular weight of 399.14 Da.
Tisolagiline
go.drugbank.com/drugs/DB21655ExperimentalThe usage of the INN stem '-giline' in the name indicates that Tisolagiline is a monoamine oxydase (MAO)-inhibitor type B. Tisolagiline has a monoisotopic molecular weight of 322.13 Da.
Mosperafenib
go.drugbank.com/drugs/DB21673ExperimentalThe usage of the INN stem '-rafenib' in the name indicates that Mosperafenib is a Raf (rapidly accelerated fibrosarcoma) kinase inhibitor. Mosperafenib has a monoisotopic molecular weight of 461.1 Da.
HNM01
go.drugbank.com/drugs/DB06531ExperimentalThe drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor. … It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase
ZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalOnce the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system[L16503] … The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest[L16503].